ESCALATE-RA A NON-INTERVENTIONAL STUDY OF CRITICAL FACTORS FOR ESCALATING DRUG TREATMENT IN PATIENTS TREATED WITH TOFACITINIB FOR MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS
Latest Information Update: 03 Aug 2024
At a glance
- Drugs Tofacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ESCALATE-RA
- Sponsors Pfizer
- 15 Jun 2024 Results of a final analysis reporting efficacy and safety data presented at the 25th Annual Congress of the European League Against Rheumatism
- 07 Sep 2023 Status changed from recruiting to completed.
- 14 Nov 2022 Interim results (data cut off-31 Jan 2022, n= 704) presented at the ACR Convergence 2022